Santen Pharmaceutical (OTC:SNPHY) and Verily, an Alphabet (NSDQ:GOOGL) company, announced that they are entering into a joint venture to focus on applying microelectronics and scalable digital technologies to ophthalmology. Osaka, Japan-based Santen and San Francisco-based Verily say they want to improve eye health globally. According to a news release, the joint venture is slated to combine […]
Santen Pharmaceuticals
Glaukos, Santen ink U.S. MicroShunt distro deal
Glaukos (NYSE:GKOS) said last Friday that it inked a multi-year distribution deal with Santen Pharmaceutical (OTC:SNPHY) to market its MicroShunt device, intended to reduce intraocular pressure in patients with primary open-angle glaucoma (POAG), in the U.S. Through the deal, San Clemente, Calif.-based Glaukos will become the exclusive U.S. distributor of the MicroShunt, which is being studied in […]
FDA rejects Santen’s intravitreal uveitis therapy
Shares in Santen Pharmaceutical (OTC:SNPHY) fell -3% today after the company’s U.S. subsidiary said that the FDA rejected the application for its intravitreal sirolimus therapy The company is developing its DE-109 product to treat people with noninfectious uveitis of the posterior segment, which can cause blindness in adults. Get the full story at our sister site, Drug […]
Santen buys microshunt maker InnFocus for $225m
Santen Pharmaceuticals said today it picked up glaucoma-treating Microshunt developer InnFocus for $225 million, plus additional consideration upon reaching certain milestones. The Microshunt system is designed to help reduce pressure within the eye in patients with moderate and late stage open angle glaucoma, and is intended to be an alternative to traditional glaucoma surgery. “The InnFocus […]
